Modality
Radioligand
MOA
KIF18Ai
Target
CD38
Pathway
Autophagy
Dravet
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
Jan 2018
→ Oct 2025
Phase 2Current
NCT07261129
640 pts·Dravet
2018-01→2025-10·Terminated
640 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-195mo agoPh2 Data· Dravet
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2025-10-19 · 5mo ago
Dravet
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07261129 | Phase 2 | Dravet | Terminated | 640 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 |